Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$9.66
0.0%
$9.57
$8.37
$13.14
N/A0.23198,987 shs652,149 shs
BeiGene, Ltd. stock logo
BGNE
BeiGene
$194.32
$148.81
$248.16
$18.03B0.57336,431 shs331,608 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$35.60
-2.5%
$34.40
$24.05
$37.69
$20.53B0.53.70 million shs3.75 million shs
Shiseido Co. stock logo
SSDOY
Shiseido
$16.33
-1.5%
$16.93
$15.32
$32.17
$6.63B0.3729,215 shs23,460 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
-0.04%+2.07%+1.11%+3.27%-7.51%
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.00%0.00%0.00%0.00%+20.79%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
-2.49%-0.75%+1.42%+9.52%+28.57%
Shiseido Co. stock logo
SSDOY
Shiseido
-1.54%-10.77%-3.77%-2.16%-42.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
1.4687 of 5 stars
3.50.00.00.00.60.80.6
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
4.9648 of 5 stars
3.64.03.33.73.51.72.5
Shiseido Co. stock logo
SSDOY
Shiseido
1.1613 of 5 stars
0.03.00.80.01.60.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00
N/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
3.00
Buy$274.20∞ Upside
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.25
Buy$48.3335.77% Upside
Shiseido Co. stock logo
SSDOY
Shiseido
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BGNE, ALPMY, SSDOY, and RPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$51.00 ➝ $54.00
5/16/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$51.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$12.56BN/A$1.80 per share5.37$5.52 per shareN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
$3.32B0.00N/AN/A$37.10 per share0.00
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.26B8.84$4.09 per share8.70$17.56 per share2.03
Shiseido Co. stock logo
SSDOY
Shiseido
$6.55B1.00$1.01 per share16.13$10.44 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$334.93M$0.1756.8014.20N/A2.65%16.55%7.35%7/29/2025 (Estimated)
BeiGene, Ltd. stock logo
BGNE
BeiGene
-$881.71M-$8.24N/AN/AN/A-25.94%-25.12%-14.95%N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$858.98M$1.8519.247.332.4348.23%24.71%13.87%8/6/2025 (Estimated)
Shiseido Co. stock logo
SSDOY
Shiseido
-$68.94M-$0.07N/A19.67N/A-0.40%-0.61%-0.30%8/6/2025 (Estimated)

Latest BGNE, ALPMY, SSDOY, and RPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$1.10N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Shiseido Co. stock logo
SSDOY
Shiseido
$0.0569$0.06+$0.0031$0.06$1.72 billion$1.54 billion
5/8/2025Q1 2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.99$1.06+$0.07$0.41$724.69 million$839.00 million
4/25/2025Q4 2025
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.1474$0.27+$0.1226$0.27$3.02 billion$3.22 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.353.62%N/A205.88%N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
N/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.882.47%N/A47.57%5 Years
Shiseido Co. stock logo
SSDOY
Shiseido
$0.080.49%N/AN/A N/A

Latest BGNE, ALPMY, SSDOY, and RPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/21/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.222.7%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.37
1.13
0.85
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.05
1.93
1.72
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.68
1.56
1.56
Shiseido Co. stock logo
SSDOY
Shiseido
0.36
1.20
0.79

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
48.55%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%
Shiseido Co. stock logo
SSDOY
Shiseido
0.02%

Insider Ownership

CompanyInsider Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
7.43%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.90%
Shiseido Co. stock logo
SSDOY
Shiseido
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,754N/AN/ANot Optionable
BeiGene, Ltd. stock logo
BGNE
BeiGene
9,00097.62 million90.20 millionOptionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
80562.24 million455.98 millionOptionable
Shiseido Co. stock logo
SSDOY
Shiseido
27,908399.66 millionN/ANot Optionable

Recent News About These Companies

Shiseido Restructures Executive Leadership in Japan
Shiseido Q1 disappoints as Drunk Elephant drags down sales
Shiseido Returns to Profit in Q1 Despite Decline in Sales
Shiseido Americas announces Interim CEO as Ron Gee resigns
Shiseido Americas CEO Ron Gee departs amid sales slowdown
Shiseido unveils mineral sun screen development

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$9.66 0.00 (-0.04%)
As of 07/16/2025 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

BeiGene stock logo

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$35.60 -0.91 (-2.49%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$35.49 -0.11 (-0.31%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Shiseido stock logo

Shiseido OTCMKTS:SSDOY

$16.33 -0.26 (-1.54%)
As of 07/16/2025 03:59 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.